Intervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist
|
|
- Maryann Horton
- 5 years ago
- Views:
Transcription
1 Intervention Study 2016 West ISD Gillian Ritchie Clinical Pharmacist
2 Introduction Annual data collection Two weeks All Medicines Management Team interventions Details recorded Classified by type Outcomes graded by significance by audit lead pharmacist
3 Wards and units included Romsey & Alton Lymington New Forest Hospital
4 Number of interventions West ISD Trust-wide West ISD Total Romsey and Alton Lymington During the 2 week study Projected number per annum 11,154 1, ,092
5 Number of interventions by type Trust-wide West ISD Total Romsey and Alton Lymington Documentation Clinical Financial NOTE: some interventions were of more than one type
6 1 Illegible 5 - Incomplete 2 Ambiguous 6 - Illegal 3 Allergy missing 7 MHA issue 4 Allergy incorrect
7
8 1 Drug omission on chart rewrite 11 Treatment duration 21 Stopping medication 2 Prescribing error on chart rewrite 12 Omissions blank box(es) 22 - Administration 3 Interactions 13 Omissions drug unavailable 23 - Compatability 4 Adverse effects 14 Omissions doses refused 24 Dispensing error 5 Drug choice 15 Omissions patient asleep 25 Incorrect drug administered 6 Swapping medication 16 Drug omission on admission 26 Drug blood levels 7 Dose 17 Drug omission on TTO 27 Physical health tests 8 Frequency 18 Fridge issues 28 - Monitoring 9 Route 19 Therapeutic duplication 29 Pt / carer counselling 10 Formulation 20 Therapeutic substitution 30 Patient identity 31 - Other
9 1 Drug omission on chart rewrite 11 Treatment duration 21 Stopping medication 2 Prescribing error on chart rewrite 12 Omissions blank box(es) 22 - Administration 3 Interactions 13 Omissions drug unavailable 23 - Compatability 4 Adverse effects 14 Omissions doses refused 24 Dispensing error 5 Drug choice 15 Omissions patient asleep 25 Incorrect drug administered 6 Swapping medication 16 Drug omission on admission 26 Drug blood levels 7 Dose 17 Drug omission on TTO 27 Physical health tests 8 Frequency 18 Fridge issues 28 - Monitoring 9 Route 19 Therapeutic duplication 29 Pt / carer counselling 10 Formulation 20 Therapeutic substitution 30 Patient identity
10 1 Cost information / analysis 2 Cost effectiveness 3 Formulary compliance
11
12 1 Intervention accepted and treatment altered 2 Intervention accepted but treatment not altered 3 Intervention accepted and recommendation actioned 4 Intervention rejected 5 Information only
13
14 1 Detrimental to patient 2 No significance to patient care 3 Significant but did not lead to improvement in standard of care 4 Significant and resulted in improvement in standard of care 5 Prevented a major organ failure or drug reaction of similar importance 6 Potentially life-saving
15
16 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Pharmacy Technician was organising medicines for TTO Patient prescribed enoxaparin 120mg once daily for 6 months for treatment of pulmonary embolism on prescription chart To continue until December 2016 Not prescribed on TTO Pharmacy Technician discussed with ward doctor Doctor added enoxaparin to TTO Potentially fatal omission of enoxaparin and communication failure with GP averted
17 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Patient prescribed rivaroxaban 20mg once daily for pulmonary embolism (PE) PE diagnosed three weeks previously Patient refusing doses Critical medicine to decrease risk of further PE Pharmacist: Discussed with nurses (patient asleep at time of pharmacist visit) Emphasised importance of patient taking rivaroxaban consistently Outcome: Patient started to take rivaroxaban again
18 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Warfarin not prescribed on admission Atrial fibrillation (AF) Pharmacist: Checked prescription charts from acute Trust for most recent warfarin doses Checked blood results for recent INR Advised dose Advised repeat INR Outcome: Critical medicine doses were not omitted Decreased risk of stroke secondary to AF
19 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Co-careldopa 12.5/50mg omitted from discharge summary Critical medicine for Parkinson s disease Continuation of Parkinson s medication vital Pharmacist: Checked medical notes Discussed with doctor Outcome: Co-careldopa added to TTO Parkinson s medication continued
20 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Elderly patient Enoxaparin 40mg daily prescribed Severe renal impairment Decreased clearance Increased risk bleeding Pharmacist: Advised doctor to switch to unfractionated heparin (UFH) Outcome: Enoxaparin switched to UFH Venous thromboembolism prophylaxis prescribed safely
21 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Elderly patient Bed bound since admission three days previously No venous thromboembolism (VTE) risk assessment completed No VTE prophylaxis prescribed Pharmacist discussed with doctor Outcome: Enoxaparin 40mg daily prescribed Decreased risk of VTE
22 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Elderly patient Prescribed multiple medications for Parkinson s Disease: Madopar hard capsules Madopar controlled release Tolcapone Naso-gastric (NG) tube and nil by mouth Patient likely to miss doses of these critical medicines / NG tube will block unless formulation changes Pharmacist: Advised doctor to switch all madopar preparations to dispersible tablets Advised doctor to switch tolcapone to equivalent entacapone dose Outcome: More evidence that crushing and dispersing entacapone in water will not alter drug effect Patient received revised treatment No loss of mobility or increase in Parkinson s symptoms
23 Very significant intervention that prevented a major organ failure or prevented a drug reaction of similar importance Elderly patient egfr 13mls/min Prescribed morphine Pharmacist: Advised Dr that risk of opiate accumulation is much higher in renal failure Switching morphine to oxycodone would significantly decrease this risk Advised re dose conversion Outcome: Morphine switched to equivalent oxycodone dose Safe and effective analgesic use in renal failure
24 Common interventions 2016 (West ISD Romsey & Alton) Transcribing errors when chart rewritten / TTOs prescribed Allergy box blank or incorrect Medicines prescribed incorrectly on admission Dose adjustments in renal impairment
25 Common interventions 2016 (West ISD Lymington) Allergy box blank or incorrect on prescription chart Paracetamol prescribed regularly and PRN Transcribing errors when chart rewritten / TTOs prescribed Enoxaparin dose incorrect due to renal impairment Dose adjustments in renal impairment Medicines prescribed incorrectly on admission
26 Common interventions 2015 (Trust-wide) Allergy box blank or incorrect Inhalers not on prescription chart Enoxaparin dose incorrect due to renal impairment Antibiotics length of course not stated Paracetamol prescribed regularly and PRN Dose adjustments in renal impairment Medicines prescribed incorrectly on admission Transcribing errors when chart rewritten / TTOs prescribed Prescriptions not signed / dated by doctor Lithium levels, clozapine levels Choice of antipsychotic & how to switch Management of side effects
27 Common interventions 2014 (Trust-wide) Allergy box blank. Enoxaparin dose incorrect due to renal failure. Inhalers not on drug chart especially salbutamol prn More than one paracetamol-containing products prescribed Psychotropic medication and QTc prolongation risk/monitoring Old doses not crossed when new ones prescribed Antibiotics length of course not stated SSRIs and NSAIDs increased risk of GI bleed Procyclidine prescribed at night
28 Common interventions 2013 (Trust-wide) Insulin not given as penfill cartridges but no pen on ward and nurses were not happy to use insulin syringes with cartridges. Allergy box blank. Enoxaparin dose incorrect due to renal failure. Calcichew formulary formulations. Clozapine side-effects especially tachycardia Type/brand of insulin not stated e.g. M3 for Humulin Brand/strength inhaler not stated. Inhalers not on drug chart especially salbutamol prn Regular benzodiazepine review requests.
29 Cost to the organisation Based on NICE economic analysis (PSG001) Costs of a medicine error - largely through increasing bed stay and increasing monitoring testing Does NOT include the cost to the individual Significant error Serious error Life threatening error ,484 1,085-2,120
30 Economic analysis Significance EQUIP SHFT 2015 SHFT 2016 Potential lethal 2% 7% 7% 930,930-1,818,960 per year 789,880-1,543,360 per year Significant 53% 79% 86% 593,190-1,368,900 per year 626,990-1,446,900 per year Total costs of SHFT interventions 1,524,120-3,187,860 per year 1,416,870-2,990,260 per year
31 Conclusions Medicines Management Team make a significant number of interventions: 429 interventions in two weeks = approximately 11,150 in a year This saves the Trust almost 3million per year All interventions were either accepted or for information only 86% were significant and improved patient care 7% either prevented an organ failure or drug reaction of similar importance, or were potentially life-saving
32 Recommendations Repeat study for two weeks in 2017 Present Divisional findings to each Division Communicate common issues identified to relevant staff: Junior doctors induction Medical and nursing staff on wards Nurses Medicines Management training days Further develop, and invest in, the Medicines Management Team: Seek to enhance level of Medicines Management service provided throughout the Trust Thereby further enhance patient safety and optimise prescribing that is both clinically- and cost-effective Thereby generate further cost savings
Intervention Study 2016 Trust-wide. Gillian Ritchie Clinical Pharmacist
Intervention Study 2016 Trust-wide Gillian Ritchie Clinical Pharmacist Introduction Annual data collection Two weeks All Medicines Management Team interventions Details recorded Classified by type Outcomes
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationMedication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016
Medication Safety Patient Safety Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016 1 The patient journey Admission Ward Transfer Ward stay Discharge Medication storage and supply
More informationAn Audit of the Post-Operative Management of Patients taking Warfarin
An Audit of the Post-Operative Management of Patients taking Warfarin Helen Wrightson Pre-Registration Pharmacist, Salisbury District Hospital March 2014 An Audit of the Post-Operative Management of Patients
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationPHARMACY INTERVENTION RECORD FORM 1.7 Medicine
Date / /20 Pharmacist initials Ward Patient Demographics (as Hospital Number) Point Admissions (A) Care of the Elderly(CE) Respiratory (R) Gastroenterology(G) Rheumatology (Rh) Endocrine (E) Other (o)
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationDrug Prescribing. Ravi Menon
Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationAim. Managing high risk medicines in primary care. Intended outcomes. Introduction. Risk associated with prescribing
Aim Managing high risk medicines in primary care To increase awareness of high risk medicines and combinations of medicines and to ensure the appropriate prescribing, supply or administration of such in
More informationMedicines Optimisation Strategy
Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic
More informationAppendix: Sample prescription form. The following sample prescription form gives examples of sections found in most hospital prescription forms.
The hands-on guide to practical prescribing Oliver Jones, Nandan Gautam Copyright 2004 by Blackwell Publishing Appendix: Sample prescription form The following sample prescription form gives examples of
More informationPatient Profile. Patient s details Initials: IF Age: 40 Gender: Male. Weight: 139.7kg Height: 510 metres BMI: >47
Patient Profile Patient background and medication list Reason for selecting profile Interesting depression case whereby there were several opportunities for intervention as a pharmacist to ensure drug-related
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationPrescribing in the Elderly. Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry
Prescribing in the Elderly Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry 24 th September 2014 Objectives Understand the significance of polypharmacy in the elderly Become familiar with the
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationGuidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationAUDIT REPORT. Salisbury District Hospital. Odstock Road. Salisbury. Wiltshire. February Page 1 of 20
AUDIT REPORT Prescribing of Treatment Dose Dalteparin Based on Patient Weight and Renal Function, and the Recording of these Parameters on the Drug Chart. Author : Location : Janeen Linsley Salisbury District
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationPrimary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationCLINICAL AUDIT. Renal Function Testing in People. Taking Dabigatran
CLINICAL AUDIT Renal Function Testing in People Taking Dabigatran Valid to December 2017 bpac nz better medicin e Background Dabigatran is an oral anticoagulant used primarily to prevent stroke in people
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationMedicine Errors. H.Beadle, L.Baxendale, Clinical Governance Pharmacists. Coventry and Warwickshire Partnership Trust Medicines Management Team
Medicine Errors H.Beadle, L.Baxendale, Clinical Governance Pharmacists Coventry and Warwickshire Partnership Trust Medicines Management Team 2015 Why Should Errors Be reported? Learning Prevention of future
More informationCommunity Pharmacy Safety in Practice Warfarin Change Package 2017
Community Pharmacy Safety in Practice Warfarin Change Package 2017 1 Community Pharmacy Safety in Practice Community Pharmacy Safety in Practice 2017/2018 is a pilot programme. We want to make it suit
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More informationDocument ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas
More informationAnticoagulation therapy : improving processes. Hilary Merrett and Fiona Gale, CHKS 18 th October 2010
Anticoagulation therapy : improving processes using risk management tools Hilary Merrett and Fiona Gale, CHKS 18 th October 2010 Risk management tools and anticoagulation therapy The applicable processes
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationDRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationEdoxaban Switch Programme - Frequently Asked Questions
Edoxaban Switch Programme - Frequently Asked Questions What should I tell patients? NHS Tayside is reviewing all patients currently receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention in
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationChange from lovenox to pradaxa
P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary
More informationMedication Reviews within Care Homes. Catherine Armstrong
Medication Reviews within Care Homes Catherine Armstrong What is a Medication Review? A structured, critical examination of a patient s medicines with the objective of reaching an agreement with the patient
More informationPrescribing Dilemmas. Sue Mulvenna Head of Pharmacy and CD Accountable Officer South Region SW 19 th May
Prescribing Dilemmas Sue Mulvenna Head of Pharmacy and CD Accountable Officer South Region SW 19 th May 2016 The four principles of medicines optimisation Aim to understand the patient s experience Evidence
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)
More informationVOLUNTARY ADMISSION BY BAYER HEALTHCARE
CASE AUTH/2490/3/12 VOLUNTARY ADMISSION BY BAYER HEALTHCARE Conduct of an employee Bayer Healthcare voluntarily admitted that a healthcare development consultant (HDC) had prepared and used three documents
More informationpatient group direction
ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationIdentifying and reducing medication errors in mental health
Identifying and reducing medication errors in mental health Hilary Scott Chief Pharmacist South Essex Partnership University NHS Trust with valuable input from Ian Maidment, Senior Lecturer in Clinical
More informationNew v1.0 Date: December 2015 Patricia Wain - Associate Director Physical Care. Kenny Laing - Deputy Director of Nursing
Clinical Venous Thromboembolism: Standing Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: New v1.0 Date: December 2015 Patricia Wain - Associate Director Physical
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationHospital Acquired VTE: update on national guidance
Hospital Acquired VTE: update on national guidance Rebecca Chanda Consultant Pharmacist - Thrombosis and Haemostasis Guy s and St Thomas Hospitals NHS Foundation Trust Chair of the UK Clinical Pharmacy
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationNEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION:
DUE CARE PROGRAM NEWSLETTER WINTER 2014 Summer 2015 Lisa Sather, RPh DUR Coordinator Mountain-Pacific Quality Health 3404 Cooney Drive Helena, MT 59602 406-457-5818 The DUE CARE PROGRAM, administered by
More informationADMINISTRATION OF INSULIN
STANDARD OPERATING PROCEDURE ADMINISTRATION OF INSULIN Issue History First issued April 2012 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote the safe administration
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationNICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationWARFARIN & OTHER ORAL ANTICOAGULANTS GUIDELINES AND PROCEDURES
WARFARIN & OTHER ORAL ANTICOAGULANTS GUIDELINES AND PROCEDURES This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances
More informationHA CONVENTION Effectiveness of Pharmacist-led Frail Elderly Medication Service in Acute Geriatric Ward
Effectiveness of Pharmacist-led Frail Elderly Medication Service in Acute Geriatric Ward HA CONVENTION 2017 Candis Chang Pharmacist Department of Pharmacy Ruttonjee and Tang Shiu Kin Hospitals Background
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationWarfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin
Warfarin in Adults : Guidelines for the use of Document Type: Clinical Guideline Clinical Lead: Ian Neilly Author/s: Ian Neilly/Paul Barbieri Directorate: Haematology Approved by Haematology Specialty
More informationA collaborative evaluation of the number and clinical significance of pharmacy interventions to the care of inpatients in Community Hospitals
East & outh East England pecialist Pharmacy ervices East of England, London, outh Central & outh East Coast Medicines Use and afety A collaborative evaluation of the number and clinical significance of
More informationMEDICINES MANAGEMENT SUB-POLICY 2: PRESCRIPTION WRITING
Edition No: 2.1 ID Number: POLCMM008 Dated: June 2015 Review Date: February 2019 Document ID: Guidelines Document Type: Corporate Directorate: Clinical Support Medicines Category: Services Management Department(s):
More informationReport to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July Gosport Hospital Report & RUH Assurance
Report to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July 2018 Title of Report: Status: Board Sponsor: Author: Appendices Gosport Hospital Report & RUH Assurance For Information Dr
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationEdoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports
More informationClinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents
Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationI. UNIFORM FORMULARY REVIEW PROCESS
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationDr Ben Edwards Consultant Anaesthetist Sheffield Teaching Hospitals
Dr Ben Edwards Consultant Anaesthetist Sheffield Teaching Hospitals 70-75,000 #NOF per annum (costs 2 billion) 10% die within 1 month 33% die within 1 year Operative delays >48hs more than doubles risk
More informationMMP016 POLICY FOR PRIMARY THROMBOPROPHYLAXIS FOR PATIENTS ADMITTED TO NHFT
MMP016 POLICY FOR PRIMARY THROMBOPROPHYLAXIS FOR PATIENTS ADMITTED TO NHFT MMP016 Policy for primary thromboprophylaxis for patients admitted to NHFT (rev Sept 2020) Page 1 of 21 Table of Contents Why
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationHot Topics: Transitions of Care
Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More information